Whole-genome Sequencing Will Cost Under $100.

Can Whole Genome Sequencing Costs Fall Below $100 By 2035?

The first sequencing of the human genome, completed in 2003, cost approximately $3 billion and required years of effort from an international consortium. Since then, advancements in sequencing technology - similar to Moore’s Law on computer chips - have dramatically reduced costs. By the early 2020s, the price of full genome sequencing had fallen below $1,000, making it viable for clinical use. Today, the industry is engaged in intense competition and innovation to further reduce this cost.

What Are The Key Factors Behind This Decline?

Currently, major providers like Illumina and BGI have significantly reduced costs thanks to high-throughput sequencing platforms. However, reaching below $100 requires not just the cost of the sequencing device but also optimization of surrounding processes such as sample preparation, quality control, data storage, and bioinformatics analysis. These supporting processes currently make up a significant portion of the total cost and slow down the rate of decline. Nevertheless, next-generation technologies like nanopore have the potential to overcome this barrier by reducing the need for vast laboratory infrastructure.

What Challenges Stand In The Way Of Reaching The $100 Threshold?

It is possible that this target will be achieved by 2035, but there are significant challenges ahead. While cost reduction follows a Moore-like curve, reaching the $100 threshold requires a steeper investment due to the physical limitations of biological processes. For example, more sensitive enzymes and microfluidic chips need to be developed to minimize error rates during DNA amplification and fragmentation. Furthermore, the cost of artificial intelligence-based analytical software must also decrease to transform the generated 100 gigabytes of raw data into a meaningful clinical report. Therefore, the mid-2030s appear as a more realistic timeframe for the maturation of both hardware and software innovations.

Forecast and Probability Assessment for 2035

According to expert estimates, there is an 85% probability that the cost of genome sequencing will fall below $100. This optimism is based on the rapid decline from 2003 to 2020 (from $3 billion to $1,000) and the development of revolutionary technologies like nanopore. However, achieving this goal requires an acceleration in the reduction of costs in supporting processes such as sample preparation and bioinformatics. 2035 stands out as a reasonable target for the completion of optimization in these supporting processes and the implementation of economies of scale.

Frequently Asked Questions

In What Country Will Sequencing Costs Below $100 First Be Applied?

It is likely that commercial or clinical services will be offered in countries like the United States, China, or the United Kingdom - nations with significant investments in genomics research. The competition between Illumina and BGI could accelerate price reductions globally.

How Will Sub-$100 Sequencing Impact Personalized Medicine?

This cost reduction would enable the integration of genomic information into routine health screenings. This would allow for the pre-determination of genetic predispositions to diseases, personalized drug dosages, and accelerated diagnosis of rare genetic disorders.

What Is The Distribution Of Current Sequencing Costs?

Currently, approximately 60-70% of the total cost is comprised of sequencing devices and reagents, while 30-40% is attributed to sample preparation, data storage, and bioinformatics analysis. Therefore, to reach the $100 target, it’s necessary to optimize not just device costs but all processes involved.